Latest Articles
Merck announces trial results for ADC that addresses unmet needs for patients with advanced endometrial cancer - PharmaLive
Merck announces trial results for ADC that addresses unmet needs for patients with advanced endometrial cancer PharmaLive
Published: May 18, 2026, 1:38 p.m.
Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer - Targeted Oncology
Sacituzumab Tirumotecan Improves Survival in Advanced Endometrial Cancer Targeted Oncology
Published: May 18, 2026, 1:33 p.m.
Expert Insights: Navigating the Influx of New Therapies in Endometrial Cancer - Pharmacy Times
Expert Insights: Navigating the Influx of New Therapies in Endometrial Cancer Pharmacy Times
Published: May 18, 2026, 1:08 p.m.
Merck’s endometrial cancer drug meets trial goals - Investing.com
Merck’s endometrial cancer drug meets trial goals Investing.com
Published: May 18, 2026, 11:15 a.m.
Merck’s Sac-TMT met primary endpoints in endometrial cancer trial - TipRanks
Merck’s Sac-TMT met primary endpoints in endometrial cancer trial TipRanks
Published: May 18, 2026, 11:10 a.m.
Merck’s endometrial cancer drug meets trial goals By Investing.com - Investing.com Canada
Merck’s endometrial cancer drug meets trial goals By Investing.com Investing.com Canada
Published: May 18, 2026, 11:01 a.m.
Merck's endometrial cancer drug meets late-stage trial goals - Reuters
Merck's endometrial cancer drug meets late-stage trial goals Reuters
Published: May 18, 2026, 10:51 a.m.
Merck's endometrial cancer drug meets late-stage trial goals - Yahoo Finance
Merck's endometrial cancer drug meets late-stage trial goals Yahoo Finance
Published: May 18, 2026, 10:51 a.m.
Merck endometrial cancer drug meets survival goals in phase 3 trial - StreetInsider
Merck endometrial cancer drug meets survival goals in phase 3 trial StreetInsider
Published: May 18, 2026, 10:47 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire
Published: May 18, 2026, 10:45 a.m.
Link copied to clipboard!